These evidences indicate the crucial role of PTMs in GBM progression and anti-PD-1 therapeutic research, prompting us to explore PTMs related biomarkers in GBM to predict the GBM occurrence and anti-PD-1 therapeutic efficiency. The gene discussed is PDCD1; the disease is glioblastoma.